December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.